These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

271 related items for PubMed ID: 9651560

  • 1. Compliance with and efficacy of treatment with pravastatin and cholestyramine: a randomized study on lipid-lowering in primary care.
    Eriksson M, Hådell K, Holme I, Walldius G, Kjellström T.
    J Intern Med; 1998 May; 243(5):373-80. PubMed ID: 9651560
    [Abstract] [Full Text] [Related]

  • 2. Comparative efficacy and safety of pravastatin and cholestyramine alone and combined in patients with hypercholesterolemia. Pravastatin Multicenter Study Group II.
    Arch Intern Med; 1993 Jun 14; 153(11):1321-9. PubMed ID: 8507122
    [Abstract] [Full Text] [Related]

  • 3. Treatment of primary hypercholesterolaemia with pravastatin: efficacy and safety over three years.
    Simons LA, Nestel PJ, Clifton P, Janus ED, Simons J, Parfitt A.
    Med J Aust; 1992 Nov 02; 157(9):584-9. PubMed ID: 1406416
    [Abstract] [Full Text] [Related]

  • 4. Diet and pravastatin in moderate hypercholesterolaemia: a randomized trial in 215 middle-aged men free from cardiovascular disease.
    Bak AA, Huizer J, Leijten PA, Rila H, Grobbee DE.
    J Intern Med; 1998 Nov 02; 244(5):371-8. PubMed ID: 9845852
    [Abstract] [Full Text] [Related]

  • 5. [Pravastatin, cholestyramine and gemfibrozil in long-term therapy of primary hypercholesterolemia. An open randomized comparative study].
    Ditschuneit HH, Dreyer M, Dammann HG, Ditschuneit H.
    Med Klin (Munich); 1991 Mar 15; 86(3):142-8. PubMed ID: 1903497
    [Abstract] [Full Text] [Related]

  • 6. Low-density lipoprotein receptor genotype-dependent response to cholesterol lowering by combined pravastatin and cholestyramine in familial hypercholesterolemia.
    Kajinami K, Yagi K, Higashikata T, Inazu A, Koizumi J, Mabuchi H.
    Am J Cardiol; 1998 Jul 01; 82(1):113-7. PubMed ID: 9671018
    [Abstract] [Full Text] [Related]

  • 7. A comparison of continuous combined hormone replacement therapy, HMG-CoA reductase inhibitor and combined treatment for the management of hypercholesterolemia in postmenopausal women.
    Ozsener S, Sendag F, Koc T, Terek MC, Oztekin K, Bilgin O.
    J Obstet Gynaecol Res; 2001 Dec 01; 27(6):353-8. PubMed ID: 11794823
    [Abstract] [Full Text] [Related]

  • 8. Fluvastatin efficacy and tolerability in comparison and in combination with cholestyramine.
    Hagen E, Istad H, Ose L, Bodd E, Eriksen HM, Selvig V, Bard JM, Fruchart JC, Borge M, Wolf MC.
    Eur J Clin Pharmacol; 1994 Dec 01; 46(5):445-9. PubMed ID: 7957541
    [Abstract] [Full Text] [Related]

  • 9. Cost-effectiveness analysis of cholesterol-lowering therapies in Spain.
    Plans-Rubió P.
    Am J Cardiovasc Drugs; 2006 Dec 01; 6(3):177-88. PubMed ID: 16780391
    [Abstract] [Full Text] [Related]

  • 10. Treatment of primary hypercholesterolaemia. Short-term efficacy and safety of increasing doses of simvastatin and pravastatin: a double-blind comparative study.
    Stalenhoef AF, Lansberg PJ, Kroon AA, Kortmann B, De Haan AF, Stuyt PM, Kastelein JJ.
    J Intern Med; 1993 Jul 01; 234(1):77-82. PubMed ID: 8326293
    [Abstract] [Full Text] [Related]

  • 11. Effect of pravastatin, an HMG CoA reductase inhibitor, and cholestyramine, a bile acid sequestrant, on lipoprotein particles defined by their apolipoprotein composition.
    Bard JM, Parra HJ, Douste-Blazy P, Fruchart JC.
    Metabolism; 1990 Mar 01; 39(3):269-73. PubMed ID: 2106607
    [Abstract] [Full Text] [Related]

  • 12. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT).
    ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.
    JAMA; 2002 Dec 18; 288(23):2998-3007. PubMed ID: 12479764
    [Abstract] [Full Text] [Related]

  • 13. Effects of pravastatin on exercise electrocardiography test performance and cardiovascular mortality and morbidity in patients with hypercholesterolemia: Lipid Intervention Study in Kyoto.
    Sasaki S, Nakagawa M, Nakata T, Azuma A, Sawada S, Takeda K, Asayama J, Lipid Intrvention Study in Kyoto.
    Circ J; 2002 Jan 18; 66(1):47-52. PubMed ID: 11999665
    [Abstract] [Full Text] [Related]

  • 14. Long-term treatment (2 years) with the HMG CoA reductase inhibitors lovastatin or pravastatin in combination with cholestyramine in patients with severe primary hypercholesterolemia.
    Jacob BG, Richter WO, Schwandt P.
    J Cardiovasc Pharmacol; 1993 Sep 18; 22(3):396-400. PubMed ID: 7504129
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and safety of pravastatin in the treatment of patients with type I or type II diabetes mellitus and hypercholesterolemia.
    Raskin P, Ganda OP, Schwartz S, Willard D, Rosenstock J, Lodewick PA, Cressman MD, Phillipson B, Weiner B, McGovern ME.
    Am J Med; 1995 Oct 18; 99(4):362-9. PubMed ID: 7573090
    [Abstract] [Full Text] [Related]

  • 16. Effect of pravastatin on cardiovascular events and mortality in 1516 women with coronary heart disease: results from the Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) study.
    Hague W, Forder P, Simes J, Hunt D, Tonkin A, LIPID Investigators.
    Am Heart J; 2003 Apr 18; 145(4):643-51. PubMed ID: 12679760
    [Abstract] [Full Text] [Related]

  • 17. Double-dose pravastatin versus add-on ezetimibe with low-dose pravastatin - effects on LDL cholesterol, cholesterol absorption, and cholesterol synthesis in Japanese patients with hypercholesterolemia (PEAS study).
    Sasaki J, Otonari T, Sawayama Y, Hata S, Oshima Y, Saikawa T, Biro S, Kono S, PEAS study investigators.
    J Atheroscler Thromb; 2012 Apr 18; 19(5):485-93. PubMed ID: 22659533
    [Abstract] [Full Text] [Related]

  • 18. Psyllium for the reduction of cholestyramine-associated gastrointestinal symptoms in the treatment of primary hypercholesterolemia.
    Maciejko JJ, Brazg R, Shah A, Patil S, Rubenfire M.
    Arch Fam Med; 1994 Nov 18; 3(11):955-60. PubMed ID: 7804477
    [Abstract] [Full Text] [Related]

  • 19. Low-dose combined therapy with fluvastatin and cholestyramine in hyperlipidemic patients.
    Sprecher DL, Abrams J, Allen JW, Keane WF, Chrysant SG, Ginsberg H, Fischer JJ, Johnson BF, Theroux P, Jokubaitis L.
    Ann Intern Med; 1994 Apr 01; 120(7):537-43. PubMed ID: 8093139
    [Abstract] [Full Text] [Related]

  • 20. Atorvastatin: an updated review of its pharmacological properties and use in dyslipidaemia.
    Malhotra HS, Goa KL.
    Drugs; 2001 Apr 01; 61(12):1835-81. PubMed ID: 11693468
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.